Form 4: Guardant Health Executive Adjusts Stock Holdings

Terilyn J. Monroe, Chief People Officer at Guardant Health, Inc., reported transactions involving restricted stock units and common stock.

Summary

• Terilyn J. Monroe, Chief People Officer of Guardant Health, Inc., has reported several transactions related to her beneficial ownership of the company's stock.
• On July 1, 2026, Monroe acquired 2,659 shares of common stock with a transaction code 'M' and a price of $0, increasing her total holdings to 23,717 shares.
• Additionally, on the same date, she acquired another 1,361 shares of common stock, also with a transaction code 'M' and a price of $0, bringing her total to 25,078 shares.
• A separate transaction on July 1, 2026, involved the disposal of 2,099 shares of common stock at a price of $170.77, reducing her directly held shares to 22,979.
• The filing also details transactions related to Restricted Stock Units (RSUs). On July 1, 2026, 2,659 RSUs were acquired (transaction code 'M'), with underlying common stock of 2,659 shares, resulting in 13,296 RSUs held.
• Another RSU acquisition of 1,361 units (transaction code 'M') on July 1, 2026, with underlying common stock of 1,361 shares, led to 9,522 RSUs held.
• The filing notes that 68 shares were acquired under Guardant Health's Employee Stock Purchase Plan on May 14, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it primarily details routine insider transactions related to executive compensation and standard equity management practices, without indicating significant positive or negative shifts in the executive's outlook on the company's performance.

Positives

• Acquisition of 2,659 and 1,361 shares of common stock at $0 cost, indicating potential equity awards or grants.
• Acquisition of Restricted Stock Units, suggesting continued incentive-based compensation for key personnel.
• Acquisition of shares through the Employee Stock Purchase Plan, demonstrating employee participation in stock ownership.

Negatives

• Disposal of 2,099 shares of common stock at $170.77 per share, which could indicate a sale of vested shares.

Risks

• The disposal of shares at $170.77 could be interpreted as a signal of potential future price moderation, though this is a common practice for executives to diversify or cover tax obligations.
• The vesting schedules for RSUs, as described in the explanations, indicate a phased release of shares over time, which is standard but means a significant portion of potential ownership is still subject to future vesting.

Future Outlook

The filing does not contain explicit forward-looking statements or guidance. However, the details regarding RSU vesting schedules imply future share releases over the next two years for the awards mentioned.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The reported acquisitions of stock and RSUs by a Chief People Officer at Guardant Health, a company in the precision oncology diagnostics sector, are typical for executive compensation and retention strategies. The disposal of shares is also a common practice for executives to manage their personal finances and diversify holdings.

Comparison to Industry Standards

• The structure of the reported transactions, including stock acquisitions, RSU grants with multi-year vesting, and share disposals, aligns with common executive compensation and equity management practices across the biotechnology and healthcare technology sectors.
• Companies like Illumina, Thermo Fisher Scientific, and other leaders in diagnostics and life sciences often utilize similar RSU and stock purchase plan mechanisms to incentivize and retain key personnel.

Stakeholder Impact

• Shareholders: The disposal of shares by an executive may be perceived by some shareholders as a signal, though it is a common practice for compensation realization and diversification.
• Employees: The participation in the Employee Stock Purchase Plan and the granting of RSUs to executives reinforce the company's use of equity as a compensation tool, potentially aligning employee and executive interests.
• Management: The transactions reflect the ongoing compensation and equity management strategies for senior leadership.

Next Steps

• Continued vesting of Restricted Stock Units over the next two years as per the described schedules.
• Potential future transactions by Terilyn J. Monroe as her equity awards continue to vest or based on personal financial planning.

Key Dates

Keywords

Guardant Health, Form 4, SEC Filing, Insider Trading, Stock Options, Restricted Stock Units, Beneficial Ownership, Terilyn J. Monroe, Chief People Officer, Employee Stock Purchase Plan, GH